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Abstract: Apolipoprotein A-IV (apoA-IV) is a lipid-binding protein, which is primarily synthesized
in the small intestine, packaged into chylomicrons, and secreted into intestinal lymph during fat
absorption. In the circulation, apoA-IV is present on chylomicron remnants, high-density lipoproteins,
and also in lipid-free form. ApoA-IV is involved in a myriad of physiological processes such as
lipid absorption and metabolism, anti-atherosclerosis, platelet aggregation and thrombosis, glucose
homeostasis, and food intake. ApoA-IV deficiency is associated with atherosclerosis and diabetes,
which renders it as a potential therapeutic target for treatment of these diseases. While much has been
learned about the physiological functions of apoA-IV using rodent models, the action of apoA-IV at
the cellular and molecular levels is less understood, let alone apoA-IV-interacting partners. In this
review, we will summarize the findings on the molecular function of apoA-IV and apoA-IV-interacting
proteins. The information will shed light on the discovery of apoA-IV receptors and the understanding
of the molecular mechanism underlying its mode of action.
Keywords: apolipoprotein A-IV; apoA-IV-interacting proteins; lipid metabolism; atherosclerosis;
platelet aggregation and thrombosis; glucose hemostasis; food intake
1. Introduction
Lipids, such as cholesterol, phospholipids, and triglycerides (TG), are insoluble in water. Therefore,
their transport in the blood, lymph, and extracellular fluid requires association with proteins that have
the capacity to interact with both lipids and water. Lipoproteins are complex particles comprised
of a central core of cholesteryl esters and TG surrounded by an outer layer of free cholesterol,
phospholipids, and apolipoproteins [1]. Apolipoprotein A-IV (apoA-IV) was originally identified as a
major protein component of chylomicrons in postprandial lymph and in the plasma of both human
and rats [2–4]. Since its discovery 40 years ago [4], numerous research using cell cultures and animal
studies has been carried out to determine the physiological roles of apoA-IV. To date, apoA-IV is
known to participate in a broad spectrum of biological processes, including lipid metabolism [5–7],
reverse cholesterol transport [8–10], protection against atherosclerosis [11–13], platelet aggregation and
thrombosis [14], glucose hemostasis [15–18], as well as food intake [19,20]. In human clinical studies,
low plasma apoA-IV concentration is associated with coronary artery disease in men [21]. High
apoA-IV pre-surgical levels are related to improved insulin sensitivity after Roux-en-Y bypass surgery,
which is an effective treatment for obesity and obesity-related co-morbidities, such as diabetes [22].
High plasma apoA-IV levels are also correlated with mild to moderate kidney failure, thereby acting as
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a predictor for kidney disease progression [23,24]. Furthermore, apoA-IV can serve as early diagnostic
biomarkers for prediabetes, liver fibrosis, and ovarian cancer [25–27]. Given the protective role against
atherosclerosis and diabetes as well as a yet unidentified role in kidney disease, apoA-IV may become
a new and effective therapeutic target for the treatment of these diseases. To achieve this goal, it
is of paramount importance to understand the molecular mechanisms by which apoA-IV exerts its
regulatory function. Notably, except platelet integrin αIIbβ3, the receptor for apoA-IV in other cell
types remains elusive [14]. In this review, we will first summarize our current understanding of
APOA4 gene, apoA-IV protein structure, apoA-IV glycation, and apoA-IV isoforms. Second, we will
discuss the cellular processes in which apoA-IV is likely involved and the signaling event it may trigger
by focusing on lipoprotein metabolism, reverse cholesterol transport, anti-atherosclerosis, platelet
aggregation and thrombosis, glucose homeostasis, and food intake. Finally, we will conclude with a
model describing pathways to which apoA-IV may contribute based on our current knowledge and
provide some perspectives on future directions.
2. APOA4 Gene and ApoA-IV Proteins
The APOA4 gene is located on chromosome 11 in human and chromosome 9 in mouse. In humans,
it is part of the gene cluster containing APOA1, APOC3, and APOA5 [28]. From 5′ to 3′ the gene order
is APOA1, APOC3, APOA4, and APO5, with the APOC3 gene transcribed from the opposite DNA
strand [28]. APOA4 is located 12 kb downstream of APOA1 and 28 kb upstream of APOA5 [28,29].
It consists of two introns and three exons spreading over 2.6 kb. The first intron separates most
of the apoA-IV signal peptide from the N-terminal mature apoA-IV protein, and the second intron
divides a highly conserved, variant amphipathic peptide repeat from the rest of the mature protein [30].
Genome-wide association (GWAS) meta-analysis from three independent cohorts (combined n ≥ 5000)
identified three independent single nucleotide polymorphisms (SNPs) from two genomic regions that
were significantly associated with apoA-IV concentrations; rs1729407 near APOA4, rs5104 in APOA4,
and rs4241819 in Kallikrein B (KLKB1) [31]. The lead SNP rs1729407 was located between APOA5
and APOA4 and one missense variant (rs5104). The missense variant rs5104 results from a serine to
asparagine substitution (Ser147Asn). Interestingly, the lead SNP rs1729407 showed an association with
HDL-cholesterol, whereas the missense SNP, rs5104 has been shown to associate with dyslipidemia in
Han Chinese [32], with postprandial apoA-I plasma concentration in healthy young men [33], and
with triglyceride in response to lipid- lowering treatment drug, fenofibrate [34]. No apoA-IV SNP
showed interaction with sex [31].
The APOA4 gene encodes a 46 kilodalton precursor of 396 amino acids, which undergoes
post-translational cleavage to yield a mature protein of 376 amino acids. It is primarily expressed in
mammalian intestine and a small portion in rodent liver [35,36]. The majority of apoA-IV production
occurs in jejunum, and it is also expressed in duodenum and ileum [37]. Additionally, it is detected
in hypothalamus and the solitary tract of the brainstem as well as dendritic cells of the immune
system [38–40]. In small intestine, APOA4 is induced by active lipid absorption. ApoA-IV protein
is synthesized in enterocytes and incorporated onto nascent TG-rich chylomicrons that are secreted
into intestinal lymph and finally drained into circulation through thoracic duct. During subsequent
hydrolysis of TG by lipoprotein lipase, most of apoA-IV dissociates from chylomicron particles. This
dissociation may be attributed to: (1) The shrinking surface area; (2) the changes in the surrounding
environment of the particles; (3) the competition for lipid binding by other exchangeable apolipoproteins
E and C (apoE and apoC). Approximately 25% of apoA-IV transfers to high-density lipoproteins (HDL)
and the rest exists in free form in the plasma [41,42].
2.1. ApoA-IV Protein Structure and Post-Translational Modifications
Human apoA-IV contains highly conserved, 22-amino-acid peptide repeats that can form
amphipathic α helices [43]. In the absence of lipids, apoA-IV self-associates to form homodimers. Each
monomeric apoA-IV protein is composed of a well-structured central core and less organized N- and
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C-termini [44]. The central helices (amino acids 64–335) are grouped into 4-helix bundles, helix-A
(aa 74–94), helix-B (aa 96–204), helix-C (aa 206–255), and helix-D (aa 265–312) [43]. Helix-B is the
longest helix and configures a rod-like structure. The N-terminal helix-A is perpendicular to helix-B
and caps one end of the rod. Following a 180◦ turn to B, helix-C and D fold into an anti-parallel helical
arm spanning approximately half the length of helix-B and are located at the other end of the rod. The
central region of the two monomers are aligned in an anti-parallel fashion with the loops connecting C
and D in each monomer opposing each other at the center of the rod. This interlocking orientation
allows the burial of hydrophobic surface on one monomer by the other at the dimer interface. It is
proposed that lipid is initially inserted into the central hydrophobic pocket of the dimer, and as more
lipids are incorporated, the helical arms consisting of helix-C and D relax away from helix-B backbone,
resulting in the formation of a circular ring and ultimately a disc-like lipoprotein particle [43]. The
N-termini and C-termini from the opposing monomer confer intermolecular interaction at one end of
the rod. They play critical roles in manipulating lipid-binding capacity of apoA-IV [44–47].
In the circulation, human apoA-IV was detected as a glycoprotein, which contains 1.8% mannose,
1.55% galactose, 1.55% N-acetyl glycosamine, and 1.1% sialic acid by weight [48]. The degree of
non-enzymatic glycation of circulating apoA-IV correlated with the severity of coronary artery disease
in diabetes patients [49]. Recombinant glycated apoA-IV (g-apoA-IV) prepared from glyoxal culture
was shown to stimulate inflammatory reactions in vitro and in vivo. Additionally, g-apoA-IV enhanced
the development of atherosclerotic lesion in apoE deficient mice that are prone to atherosclerosis [49].
Mutation in major glycation sites dampened the atherogenic effect of g-apoA-IV. Together, it suggests
glycation of apoA-IV adversely influences its anti-atherosclerosis function.
2.2. Genetic Variants of ApoA-IV in Human Population
In humans, seven genetic variants have been identified, including apoA-IV-1, apoA-IV-1A,
apoA-IV-2, apoA-IV-2A, apoA-IV-3, apoA-IV-0, and apoA-IV-5 [50]. ApoA-IV-1 is the most common
isoform. ApoA-IV-1A encodes a T347S substitution near the C-terminus and has the same electrophoretic
mobility as the parent isoform apoA-IV-1. It may facilitate the intravascular clearance of TG-rich
lipoproteins at postprandial state, likely due to its reduced lipid-binding affinity based on structure
prediction [51]. Several population studies reported lower plasma total cholesterol, LDL, and lower
lipoprotein levels in carriers of the T347S allele than those homozygous in 347T [50]. ApoA-IV-1A
was also associated with lower plasma apoA-IV concentration and increased risk of coronary heart
disease [52]. ApoA-IV-2 is derived from a Q360H substitution at the C-terminus, introducing one
more basic charge unit to apoA-IV-1. ApoA-IV-2 protein displays higher lipid affinity than apoA-IV-1.
In contrast to apoA-IV-1A, it delayed the postprandial clearance of TG-rich lipoproteins [53]. Many
population studies showed that people with the Q360H allele have increased HDL cholesterol, reduced
LDL cholesterol, lower fasting plasma TG, lower apoA-I level, and higher fasting glucose and insulin
levels [50]. Conversely, some other studies did not observe any effect on plasma lipids and lipoproteins.
Although apoA-IV-2 cannot act as an independent risk factor for cardiovascular diseases in patients
with normal lipid levels [54], it could promote atherosclerosis in patients with hyperlipidemia resulting
from metabolic disorders, such as obesity, or familial combined hyperlipidemia [55,56]. ApoA-IV-1,
apoA-IV-1A, and apoA-IV-2 are the top three frequent isoforms in human populations worldwide. A
highly conserved domain containing a repeated series of EQ(Q/A/V)Q-type tetrapeptides is present at
the C-terminus (aa 340–370) of mammalian apoA-IV proteins [57]. ApoA-IV-2A has a deletion at the
second EQQQ motif at position 361, whereas apoA-IV-0 and apoA-IV-5 both encode an insertion of
EQQQ motif at position 361 with apoA-IV-5 possesses additional G to T substitution at codon 317.
ApoA-IV-3 is a two-charge shifted isoform. Polymorphisms that code for E24K or E165K or E230K
substitution have been reported as apoA-IV-3 [51,58,59].
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3. ApoA-IV Function in Cells
3.1. ApoA-IV and Lipoprotein Metabolism
ApoA-IV plays a role in modulating TG-rich lipoprotein assembly and metabolism. Of the major
apolipoproteins produced by the gastrointestinal tract (apoA-I, apoA-IV, and apoB48), apoA-IV is the
most responsive to lipid ingestion [60,61]. The induction of apoA-IV synthesis is mediated through
absorption of long-chain fatty acids, but not short-chain fatty acids, which are transported via portal
blood and do not elicit chylomicron production [62]. Upon lipid feeding, apoA-IV is assembled
into nascent chylomicrons in the intestinal enterocytes [63]. To understand apoA-IV’s role in lipid
absorption and packaging, the Black group transiently expressed apoA-IV in newborn swine intestinal
epithelial cells IPEC-1 [6]. They found that apoA-IV overexpression caused a great increase in the
secretion of TG, cholesteryl ester, and phospholipids in the chylomicron particles. They further
expressed apoA-IV under an inducible promoter in IPEC-1 and showed that apoA-IV enhanced TG
secretion in a dose-dependent manner, leading to the formation of larger TG-rich chylomicrons [64].
In the same study, they demonstrated that a region from residues 344 to 354 in human A-IV was
essential for its ability to promote TG secretion while the C-terminal EQQQ-rich region played an
inhibitory role. Apolipoprotein B is another key component of chylomicron particles and is critical
for chylomicron assembly and secretion. Prechylomicron formation involves lipidation of apoB by
microsomal triglyceride transfer protein (MTP) in the endoplasmic reticulum (ER) of enterocytes [65].
These prechylomicron particles, which also contain ApoA-IV on their surface, are later transported
to Golgi apparatus, where they receive large amount of additional TG and expand their size before
exocytosis [63,65]. When apoA-IV was restricted in the ER of McA-RH7777 rat hepatoma cells, apoB
trafficking from ER to Golgi was dramatically reduced, resulting in decreased apoB secretion as well as
TG secretion [7,66]. In contrast, over-expression of rat apoA-IV increased apoB secretion, enhanced
apoB-containing particle expansion, and TG secretion [7,66]. This indicated that apoA-IV interacted
with apoB in the secretory pathway to regulate TG-rich lipoprotein secretion. Interestingly, in vivo
studies using apoA-IV knockout or transgenic mice revealed that alteration of apoA-IV levels did not
change dietary lipid absorption [67,68]. However, loss of function of apoA-IV affected chylomicron
assembly and metabolism as apoA-IV–/– mice secreted larger chylomicrons and chylomicrons from
apoA-IV–/– mice were cleared more slowly from the plasma than WT chylomicrons [69].
ApoA-IV promotes lipoprotein lipase activity in the presence of apoC-II-containing lipoproteins [5].
Lipoprotein lipase (LPL) is an enzyme that hydrolyzes TG in TG-rich lipoproteins into one
monoacylglycerol and two free fatty acids, which are subsequently taken up by muscle for utilization
or by adipose tissue for storage [70]. LPL is synthesized and secreted by parenchymal cells in
peripheral tissues and attached to luminal surface of capillary endothelial cells where it interacts
with lipoproteins in the bloodstream [70]. LPL activation requires apolipoprotein C-II, a surface
component of chylomicrons, very low-density lipoproteins (VLDL), and HDL [71]. In the presence of
VLDL/HDL, LPL activity was enhanced by apoA-IV when either TG emulsion or TG-rich lipoproteins
from apoC-II deficient subject was used as substrate [5]. In the absence of an apoC-II source, apoA-IV
no longer promoted LPL activity. Moreover, it was the lipid-free form of apoA-IV that was functional
as saturating lipoprotein-unassociated apoA-IV with lipids markedly reduced its ability to activate
LPL activity.
3.2. ApoA-IV and Reverse Cholesterol Transport
Reverse cholesterol transport (RCT) involves a series of events resulting in the transport of
excessive cholesterol from peripheral tissues back to the liver for excretion in the bile and eventually
the feces [72]. It begins with the transfer of cellular cholesterol within peripheral cells to extracellular
HDL-based acceptors via the action of lipid transporters, such as ATP-binding cassette transporters
ABCA1 and ABCG1. Cholesterol efflux in peripheral tissue can occur in a number of ways [73]: (1) Efflux
to nascent, lipid-poor HDL via ABCA1; (2) efflux to mature HDL formed as a result of esterification
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of free cholesterol in HDL, via ABCG1; (3) efflux to mature HDL mediated through other pathways,
including possibly scavenger receptor class B type I (SR-BI) and passive diffusion. Free cholesterol in
HDL is converted to cholesteryl ester by an enzyme named lecithin:cholesterol acyltransferase (LCAT).
This conversion provides the driving force for more free cholesterol to move along concentration
gradient from plasma membrane to HDL in the extracellular space [74]. Cholesteryl ester-containing
HDL is subsequently absorbed by the liver through SR-BI. Alternatively, cholesteryl ester is transferred
from HDL by cholesteryl ester transfer protein (CETP) to apoB-containing lipoproteins [75], which are
later delivered to and taken up by the liver via VLDL/LDL receptors [73,76].
Several lines of evidence have indicated that apoA-IV promotes cholesterol efflux in cultured cells.
Using human skin fibroblasts cultured in the medium with [3H]cholesterol-labeled serum, apoA-IV
was shown to increase cholesterol efflux in the presence of phospholipids-containing liposomes [9]. The
effect of apoA-IV was comparable to that of apoA-I and apoE at physiological relevant concentrations. In
adipose cells preloaded with LDL cholesterol, both artificial and native apoA-IV-containing lipoprotein
particles were able to enhance cholesterol removal as a function of time and concentration [10].
Using cultured primary macrophages with preloaded radiolabeled cholesterol, HDL-sized lipoprotein
particles from apoA-IV transgenic mice conferred greater ability to reduce cellular cholesterol content
than those from WT mice [12]. ApoA-IV increased cholesterol efflux in HeLa cells overexpressing
human ABCA1, indicating that apoA-IV participates in ABCA1-mediated cholesterol efflux [77].
Analysis using N-terminal or C-terminal deletion mutants of apoA-IV further revealed that the
C-terminal domain (aa 333–376) inhibits apoA-IV’s ability to promote cholesterol efflux [78].
ApoA-IV can activate LCAT and enhance cholesterol esterification rates [8,12]. LCAT catalyzes
the transfer of the acyl group from the β-position of phosphatidylcholine (a class of phospholipids) to
the hydroxyl group of cholesterol, leading to the production of lysolecithin and cholesteryl ester [79].
By using purified LCAT and phospholipid/cholesterol/[4-14C]cholesterol-containing liposome, human
apoA-IV was proven to facilitate LCAT activity [8]. ApoA-I and apoA-IV are the two most efficient
co-factors for LCAT activity [80]. However, apoA-IV differs from apoA-I in terms of acyl donor.
ApoA-IV was a more potent activator of LCAT than apoA-I with L-α-phosphatidylcholine substituted
with two saturated fatty acids. Whereas apoA-I acted stronger than apoA-IV with egg yolk lecithin,
L-α-dioleoylphosphatidylcholine and L-α-phosphatidylcholine esterified with one saturated and one
unsaturated fatty acids. By incubating the plasma with [3H]cholesterol followed by quantification
of radiolabels incorporated into cholesteryl ester, mouse apoA-IV transgenic mice showed higher
cholesterol esterification rates than WT mice, indirectly supporting apoA-IV-mediated LCAT activation
in vivo [12]. Structure–function analysis revealed that partial removal (∆aa 117–160) of the amphipathic
α helices region of apoA-IV markedly decreased LCAT activation by apoA-IV [78]. This suggests that
residues 117–160 in the amphipathic helical sequences are involved in LCAT activating function of
apoA-IV and thus critical for the properties of apoA-IV in RCT.
ApoA-IV increases human plasma CETP activity in vitro [81]. In humans, CETP is central to the
alternative pathway of delivering cholesteryl ester in HDL to the liver and thereby influencing the
overall rate of RCT [73,82,83]. Using lipid microemulsion, the activity of CETP was determined in
the presence of apoA-IV. Cholesteryl ester transfer rate was directly proportional to the amount of
apoA-IV on the surface of the lipid emulsion, indicating that apoA-IV activated CETP [81]. By studying
apoA-IV mutants with truncations in various α helical regions, Weinberg et al. found that, rather than
specific helical region, molecular interfacial exclusion pressure accounted for apoA-IV’s function in
CETP activation [84].
3.3. ApoA-IV and Atherosclerosis
Over-expression of apoA-IV prevents mice from atherosclerosis. Transgenic mice over-expressing
human apoA-IV in the liver of C57BL/6 strain and apoE knockout (apoE–/–) strain showed
significantly reduced atherosclerotic lesion by a mechanism that did not involve increased HDL
cholesterol concentration [11]. Similarly, expressing human apoA-IV in the intestine of apoE-deficient
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background (apoA-IV/E0 mice) protected the mice from atherosclerosis without an increase in HDL
cholesterol [13]. Mouse apoA-IV over-expression engendered the same effect on the formation
of atherogenic diet-induced aortic lesion [12]. Three possible mechanisms have been suggested
for the anti-atherosclerotic action of apoA-IV. One is the role of apoA-IV in promoting reverse
cholesterol transport, which has been reviewed previously. The other two are the anti-oxidant and
anti-inflammatory activities of apoA-IV, which will be described as follows.
3.4. ApoA-IV and Lipoprotein Oxidation
ApoA-IV serves as an inhibitor of lipoprotein oxidation [12,13,85,86]. Oxidation of lipids in
low-density lipoproteins (LDL) is a key stage in the initiation of atherosclerosis [87–89]. LDL enters into
subendothelial space and is oxidized by mechanisms involving free radicals and/or lipoxygenases [87].
Free radicals can come from several sources: Free metal ion, low-molecular weight complexes of
metal ions, superoxide, thiols, peroxynitrite, or nitric oxide [87]. Lipoxygenases catalyze the oxidation
of polyunsaturated fatty acids in lipids [90]. Oxidized LDL attracts monocytes to migrate across
epithelium and into artery wall, where the cells differentiate into macrophages. Macrophages take
up oxidized LDL via scavenger receptors and become foam cells, a hallmark of atherosclerotic
lesion. Macrophages also secrete myeloperoxidase, an enzyme catalyzing the formation of reactive
oxygen intermediates that also triggers LDL oxidation. Using fasting lymph to mimic interstitial
fluid in the subendothelial space, Qin et al. determined that metal ion (Cu2+)-induced oxidation of
lymph lipoproteins or purified LDL was inhibited by rat apoA-IV in a dose-dependent manner [85].
Meanwhile, macrophage-mediated oxidation of lymph lipoproteins was reduced by apoA-IV. The
antioxidant property of apoA-IV was also indicated by the finding that apoA-IV/E0 mice had decreased
LDL aggregation and less oxidized LDL than WT [13]. Given that oxidized LDL induces the migration
of monocytes to artery wall, Cohen et al. evaluated the degree of LDL oxidation by counting the
number of transmigrating monocyte in a co-culture model of the artery wall [12]. Using this co-culture
system, consisting of a monolayer of endothelial cells, smooth muscle cells, and an extracellular matrix
in between, they found that LDL treatment stimulated a five-fold increase in monocyte migration
compared to mock treatment. When LDL treatment was combined with HDL particles from apoA-IV
transgenic mice, monocyte migration was reduced to a greater extent than LDL with HDL particles
from control mice, implying the inhibitory function of apoA-IV on LDL oxidation. Using VLDL and
apoA-IV purified from human plasma, human apoA-IV also prevented Cu2+-induced oxidation as
well as 2,2’-Azobis(2-amidinopropane) dihydrochloride-induced oxidation of VLDL [86].
ApoA-IV regulates intracellular glutathione redox balance and thus mitigates oxidant-induced
apoptotic cell death [91]. In mitotic competent, undifferentiated pheochromocytoma (PC12)
cells, pretreatment with apoA-IV attenuated tert-butyl hydroperoxide (TBH), or thiol oxidant
diamide-induced apoptosis. Oxidant-induced apoptosis is consistently associated with oxidant-induced
glutathione (GSH)/glutathione disulfide (GSSG) imbalance [92]. Decreased GSH to GSSG ratio
precedes the activation of mitochondrial apoptotic pathway, which involves loss of mitochondrial
integrity, mitochondrial cytochrome c release, and cysteine protease (caspase)-3 activation [93].
GSH predominantly exists in the reduced thiol form, and is oxidized to GSSG under oxidizing
conditions. Cellular GSH homeostasis is maintained through three means [93], de novo synthesis of
GSH, uptake of GSH from exogenous resources across plasma membrane, and catalytic reduction of
GSSG by GSSG reductase, which utilizes NADPH generated from the action of glucose-6-phosphate
dehydrogenase (G6PD). The Kalogeris group discovered that ApoA-IV decreased TBH-elicited GSSG
production and increased GSH levels in PC12 cells [91]. ApoA-IV did not affect de novo synthesis
of GSH, as blockage of this pathway by DL-Buthionine-(S,R)-sulfoximine did not alter apoA-IV
anti-apoptotic function. ApoA-IV did not change cellular GSSG reductase activity, either. Nonetheless,
it stimulated a 10-fold increase in G6PD expression and conferred G6PD-dependent protection against
oxidant-mediated apoptosis.
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ApoA-IV acts as an anti-inflammatory agent to alleviate experimental colitis. Dextran sulfate
sodium (DSS) treatment induces inflammation and acute colitis in mice. ApoA-IV substantially
postponed the onset, and diminished the severity and extent of inflammatory response elicited by
DSS [94]. ApoA-IV–/– mice were more susceptible to DSS-induced inflammation, whereas exogenous
administration of apoA-IV to apoA-IV–/– in mice reversed the outcome. DSS is thought to trigger
mucosal injury and confer toxicity on epithelial cells, leading to the recruitment and activation of
inflammatory cells, upregulation of inflammatory mediators, and eventually the development of
severe colitis [95]. ApoA-IV could significantly reduce DSS-induced leukocyte and platelet adhesive
interactions, an important initial step for recruiting leukocyte to the site of injury or infection. Stimulated
endothelial cells or activated platelet at the site of injury express P-selectin, a protein belonging to
selectin family of cell adhesive molecules, at the plasma membrane. The interaction between P-selectin
and P-selectin glycoprotein ligand-1 (PSGL-1) expressed on the cell surface of leukocytes guides the
tethering and rolling of leukocytes on the endothelial cells as well as heterotypic platelet aggregation
on the leukocytes [96]. The inhibitory role of apoA-IV on leukocyte and platelet adhesion was likely
attributed to the downregulation of P-selectin.
3.5. ApoA-IV Inhibits Platelet Aggregation and Thrombosis
As the most abundant integrin in platelet, αIIbβ3 is required for platelet aggregation [97,98].
Integrins are ubiquitous transmembrane α/β heterodimeric receptors that mediate cell-to-cell and
cell-to-extracellular matrix interactions upon binding to respective ligands [99]. They are present
in platelets to support platelet adhesion to the extracellular matrix proteins [100–102]. In normal
circulation, platelets exist in the non-adhesive “resting” state and become activated upon vascular injury,
under which conditions platelets are exposed to immobilized adhesive proteins in the extracellular
matrix or soluble platelet agonists [98]. Platelet activation leads to the conformational change of αIIbβ3
integrin followed by increased binding affinity to its ligand, such as fibrinogen (Fg), fibronectin, von
Willebrand Factor (VWF), and many matrix proteins containing arginine-glycine-aspartic acid-like
sequences. The ligands, such as Fg, mediate platelet adhesion and aggregation by bridging αIIbβ3
integrin in adjacent platelets [97,98]. It also triggers downstream intracellular signaling pathways,
resulting in platelet spreading, granule secretion, stable adhesion, and clot retraction. Integrin
αIIbβ3-mediated platelet aggregation is indispensible for hemostatic thrombi formation, which is used
to stop bleeding and preserves vascular integrity and function. However, when it is dysregulated,
thrombosis occurs, obstructing blood flow in the blood vessels and increasing the risk of heart attack
or stroke.
ApoA-IV negatively regulates αIIbβ3-mediated platelet aggregation and thrombosis [14]. Using
recombinant apoA-IV and platelet-rich plasma isolated from apoA-IV–/– mice and apoA-IV transgenic
mice, apoA-IV was proven to prevent Fg-dependent and Fg/VWF-independent platelet aggregation
in vitro [14]. This is likely mediated through blockage of αIIbβ3-ligand interaction by apoA-IV.
ApoA-IV also adversely affected αIIbβ3-mediated granule release and indirectly inhibited P-selectin
expression on the platelet surface. Structure–function analysis revealed that the N-terminal region
(aa 1–38) of apoA-IV was critical for apoA-IV binding to αIIbβ3 and inhibition of platelet aggregation,
whereas the C-terminal region (aa 336–376) negatively modulated apoA-IV binding to αIIbβ3 through
inter-molecular interactions [14]. Moreover, two conserved aspartic acids at position 5 and 13 at the
N-terminus were potential recognition sites of αIIbβ3 and necessary for apoA-IV inhibitory function.
Since platelet aggregation is a prerequisite for thrombosis, apoA-IV was shown to attenuate thrombus
growth and promote thrombus dissolution in vitro and in vivo [14]. The inhibitory effect of apoA-IV
on thrombosis is similar to that of aspirin and clopidogrel, two well-established medications to reduce
blood clot formation. In addition, apoA-IV was able to prevent postprandial platelet hyperactivity
induced by high-fat diet consumption in vivo [14].
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3.6. ApoA-IV and Glucose Metabolism
ApoA-IV improves glucose homeostasis by promoting insulin secretion at high levels of
glucose [15]. Under high-fat diet feeding, apoA-IV–/– mice showed reduced insulin secretion and
impaired glucose tolerance. By injecting recombinant apoA-IV into apoA-IV–/– mice, compromised
insulin secretion was rescued and glucose tolerance was improved. In addition, injecting apoA-IV into
diabetic KKAy mice caused the similar glucose-lowering effect, suggesting apoA-IV had the ability
to modulate glucose homeostasis. β-cells in pancreatic islets are responsible for glucose-stimulated
insulin secretion [103]. After food ingestion, circulating glucose enters β-cells through passive diffusion
and undergoes catabolism to generate ATP. The change in cellular ATP/ADP ratio resulting from
elevated glucose metabolism triggers the closure of ATP-sensitive K+ (KATP) channel and depolarizes
the plasma membrane, leading to the activation of Ca2+ channels. The influx of ionized Ca2+ into the
cytoplasm eventually stimulates the exocytosis of readily releasable insulin-containing granules [104].
Apart from KATP channel-dependent pathways, other secondary messengers, such as cyclic adenosine
monophosphate (cAMP) and diacylglycerol (DAG), can augment insulin release in the presence of
ionized Ca2+ [104]. Recombinant apoA-IV directly enhanced insulin secretion in isolated mouse
pancreatic islets under conditions of high glucose but not low glucose. This enhancement involved
the regulation of cAMP levels, which affects Ca2+-dependent insulin secretion. However, it remains
unresolved how apoA-IV enhances cAMP pathway. We speculate the existence of an apoA-IV
receptor, to which apoA-IV binds and initiates downstream signaling pathway that results in elevated
cAMP levels.
ApoA-IV promotes glucose uptake in mouse adipocytes via PI3K-Akt signaling pathway [18].
In the absence of insulin, glucose transporter Glut4 in peripheral cells recycles slowly between the
plasma membrane and intracellular vesicular compartments, where most Glut4 resides [105]. In
response to increased blood glucose levels, insulin is secreted from pancreatic islets, circulates to
peripheral cells, and stimulates the enrichment of Glut4 at the plasma membrane, which facilitates
the uptake of glucose. The translocation of Glut4 is mediated through a complex cascade of signaling
events [106]. Insulin binds to insulin receptor on the plasma membrane of peripheral cells and
activates the tyrosine kinase domain of insulin receptor, which phosphorylates the tyrosine residues
of intracellar substrates, including the insulin receptor substrate family (IRS1-4). Phosphorylated
IRS interacts with and activates the phosphatidylinositol 3-kinase (PI3K) signaling pathway to
generate the lipid product phosphatidylinositol 3,4,5-triphosphate (PIP3), which subsequently activates
phosphoinositide-dependent kinase 1 (PDK1). Activated PDK1 then phosphorylates protein kinase
B (also known as Akt) and initiates Akt signaling. PI3K/Akt signaling pathways play essential
roles in Glut4 translocation and glucose uptake [106]. Recombinant apoA-IV treatment on WT mice
improved glucose uptake significantly in cardiac muscles, visceral white adipose, and brown adipose
tissues [18]. In contrast to WT, apoA-IV–/– mice had lower glucose uptake rates in tibialis anterior,
extensor digitorum longus, and soleus muscles, indicating that apoA-IV contributes to efficient glucose
uptake in muscles [18]. In 3T3-L1 adipocytes, apoA-IV treatment upregulated Glut4 translocation
and glucose uptake in the absence of insulin [18]. ApoA-IV stimulated the expression of Akt as
well as the phosphorylation of Akt in a time- and dose-dependent fashion. Blocking PI3K signaling
via wortmannin abolished apoA-IV-stimulated Akt phosphorylation and decreased glucose uptake,
suggesting PI3K signaling might contribute to the activation of Akt by apoA-IV. Together, apoA-IV
appears to act independently from insulin to trigger PI3K/Akt signaling in adipocytes. Further studies
are needed to test whether apoA-IV’s action is mediated through insulin receptor.
ApoA-IV suppresses hepatic gluconeogenesis through interaction with the nuclear receptors,
nuclear receptor subfamily 1 group D member 1 (NR1D1) and nuclear receptor subfamily 4 group A
member 1 (NR4A1) [16,17]. During short-term fasting, liver generates and releases glucose into the
bloodstream mainly through glycogenolysis. During prolonged fasting when glycogen has already
been depleted, liver produces glucose via de novo synthesis (gluconeogenesis) using lactate, pyruvate,
glycerol, and amino acids as substrates [107]. Based on these substrates, a series of enzymatic events
Cells 2019, 8, 319 9 of 18
occurs during gluconeogenesis to synthesize glucose [107]. Among them, the conversion of oxaloacetate
to phosphoenolpyruvate by phosphoenolpyruvate carboxykinase (PEPCK) is a key step. Another
rate-limiting step is the dephosphorylation of glucose 6-phosphate by glucose-6-phosphatase (G6Pase)
to release glucose. In apoA-IV–/– mice, both G6Pase and PEPCK gene expressions were significantly
higher than those in WT mice. In primary hepatocytes, recombinant apoA-IV treatment reduced
G6Pase and PEPCK mRNA levels. The suppression of gluconeogenic gene expression by apoA-IV
was mediated through NR1D1, also known as Rev-erbα, which is a nuclear receptor and transcription
factor that regulates glucose homeostasis by repressing the expression of hepatic gluconeogenic genes
including PEPCK and G6Pase [108,109]. ApoA-IV was shown to interact with NR1D1 in the nucleus of
human HepG2 cells. With NR1D1, apoA-IV was bound to the RORα response element (RORE) of the
human G6Pase promoter region to initiate transcriptional repression. Also, apoA-IV stimulated NR1D1
expression in mouse primary hepatocytes as well as HepG2 and HEK-293 cells [16]. In conclusion,
apoA-IV interacted with NR1D1 to downregulate gluconeogenic genes and thus reduced the release of
hepatic glucose to the bloodstream. NR4A1 was shown to interact with apoA-IV in vitro as well [17].
ApoA-IV–NR4A1 complexes colocalized near the RORE element of the human G6Pase promoter to
reduce transcriptional activity. ApoA-IV increased NR4A1 expression in primary mouse hepatocytes
as well as in the mouse liver [17]. Therefore, NR1D1 and NR4A1 may serve complementary roles in
apoA-IV-mediated suppression of hepatic gluconeogenesis.
3.7. ApoA-IV and Food Intake
Inhibition of food intake by apoA-IV is mediated centrally in rats. It was reported that
intracerebroventricular (ICV) injection of recombinant apoA-IV significantly and dose-dependently
suppressed food intake [19]. By contrast, ICV administration of anti-rat apoA-IV serum enhanced
food intake, even during the light cycle when rats usually do not eat. Later, both apoA-IV mRNA and
proteins were detected in rat hypothalamus [39], where the signals for regulating food intake and energy
homeostasis are integrated [110]. In particular, apoA-IV protein was present in the arcuate nucleus,
ventromedial hypothalamic (VMH), paraventricular and dorsomedical areas of the hypothalamus, as
well as the solitary tract of the brainstem [40]. The anorectic effect of apoA-IV mostly occurs in the central
nervous system because circulating apoA-IV could not cross the blood–brain barrier [40]. Although
peripheral administration of apoA-IV also suppressed food intake, the satiation signal was transmitted
to the brain via intact vagus nerve [111]. Recently, the activation of hypothalamic PI3K signaling
pathway has been implicated in leptin- or insulin-induced anorexia [112–114]. Activated PI3K triggers
the phosphorylation of Akt and subsequent downstream signaling. In cultured primary hypothalamic
neurons, apoA-IV increased the levels of phosphorylated Akt in a time- and dose-dependent manner [20].
This effect was abrogated by pre-incubation with PI3K inhibitor LY294002, suggesting apoA-IV
stimulated PI3K-mediated Akt phosphorylation. The satiation effect of apoA-IV through PI3K/Akt
signaling pathway was recapitulated in rats when ICV administration of apoA-IV was performed [20].
More specifically, the brain area responsive to apoA-IV action is VMH. In high-fat diet-induced obese
rats, apoA-IV action on feeding was blunted and PI3K/Akt pathway was impaired in VMH, implying
that a defective PI3K/Akt pathway in these obese rats may be responsible for reduced anorectic effect
of apoA-IV [20].
4. ApoA-IV Interacting Partners
4.1. ApoA-IV Binding to Cell Surface of Several Cell Lines
ApoA-IV, together with apo A-I, A-II, C-I, C-II, CIII, and E, are major protein components
of HDL [115]. HDL is closely involved in reverse cholesterol transport by mediating cholesterol
efflux from peripheral cells and transporting excessive cholesterol to the liver [116]. In adult bovine
aortic endothelial cells (ABAE) to which human HDL binds, free apoA-IV as well as apoA-I were
able to bind to and displace HDL on the cell surface [117]. This binding was enhanced in the
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presence of 25-hydroxycholeterol, which induces a 3- to 10-fold increase in HDL binding sites at
the surface of vascular endothelial cells [118]. In mouse adipose cells where apoA-IV-phospholipid
complexes promote cholesterol efflux, apoA-IV bound to specific cell surface sites with a Kd value
of 0.32 × l0−6 M [10]. The maximum binding capacity for apoA-IV per cell is 223,000 sites. These
recognition sites appeared to be also shared by apoA-I and apoA-II. In primary rat hepatocytes,
apoA-IV-phospholipid complexes could bind to cell surface and were internalized [119]. The binding site
was distinct from apoE receptor sites, indicating that apoA-IV may be responsible for apoE-independent
HDL uptake by the liver. A few apoA-IV binding partners have been identified, but whether apoA-IV
interacts with distinct binding patterns in each target tissue to mediate its pleiotropic actions remains
to be determined.
4.2. ApoA-IV Binding to NR1D1 and NR4A1 in Human Hepatic Carcinoma Cell Line
Rat apoA-IV was identified to interact with NR1D1 in the bacteria two-hybrid library screening
using rat liver cDNA library [16]. In HepG2 cells treated with exogenous GFP-conjugated recombinant
human apoA-IV, Li et al. showed that the GFP signal colocalized with endogenous human NR1D1 in
the cytoplasm as well as in the nucleus [16]. Using in situ proximity ligation assay, which marked
the location of interaction in the cell, apoA-IV binding to NR1D1 was confirmed in the cytoplasm
and the nucleus. When nuclear proteins from HepG2 cells treated with GFP-tagged apoA-IV are
used for co-immunoprecipitation, NR1D1 was pulled down by antibodies against GFP, suggesting
direct interaction between NR1D1 and apoA-IV. Considering NR1D1 is a nuclear receptor, it was
proposed that exogenous human apoA-IV could be taken up by hepatocytes and interacts with NR1D1
inside the cell [16]. Using proximity ligation assays and co-immunoprecipitation, NR4A1 was also
shown to interact with apoA-IV in HepG2 cells [17]. The physical interaction between apoA-IV and
NR1D1/NR4A1 lays a foundation for the inhibitory function of apoA-IV in hepatic gluconeogenesis,
which has been reviewed in Section 3.5.
4.3. ApoA-IV Binding to αIIbβ3 Integrin
Human apoA-IV has recently been found to be a novel ligand for platelet αIIbβ3 integrin in the
search of human plasma protein binding to activated αIIbβ3 [14]. ApoA-IV bound to the cell surface of
the activated platelet but not the resting platelet, and this binding was dependent on activated αIIbβ3.
Unlike other known ligands for αIIbβ3 integrin, such as Fg and fibronectin, apoA-IV interaction
with the platelet did not cause its internalization. However, apoA-IV could compete with Fg for
binding to αIIbβ3 integrin on the platelet. The binding affinity of apoA-IV to αIIbβ3 was about
40% of the affinity between Fg and αIIbβ3. In a reciprocal way, Fg decreased apoA-IV binding to
αIIbβ3. The arginine-glycine-aspartic acid peptide, which is the canonical integrin binding motif, also
inhibited apoA-IV binding to αIIbβ3 in a dose-dependent manner. However, it is unknown whether
αIIbβ3-interacting apoA-IV is associated with lipids or not.
5. Conclusions
In summary, as a protein synthesized primarily in the intestine, apoA-IV enters into circulation
through chylomicrons, affects the metabolism of lipoproteins, and exhibits anti-atherogenic or
anti-diabetic effect in the circulation and peripheral tissues. ApoA-IV is able to attenuate atherosclerosis
probably through three different routes (Figure 1): (1) By affecting HDL-mediated reverse cholesterol
transport; (2) by reducing LDL oxidation; (3) by suppressing inflammatory responses probably
through P-selectin pathway and platelet aggregation via αIIbβ3 integrin-mediated signaling. ApoA-IV
influences the regulation of blood glucose levels in three different organs (Figure 2). In the pancreas, it
potentiates glucose-stimulated insulin secretion via a pathway involving cAMP and downstream of
Ca2+-mediated exocytosis of insulin-containing granules (Figure 2A). In adipose tissue, it promotes
glucose uptake through activation of PI3K/Akt pathway and subsequent Glut4 translocation to the
plasma membrane (Figure 2B). In the liver, it inhibits gluconeogenesis via interaction with NR1D1
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and/or NR4A1 and repression of gluconeogenesis genes (Figure 2C). Central apoA-IV modulates food
intake in the hypothalamus through PI3K/Akt pathway (Figure 3). Peripheral apoA-IV probably
synchronizes via the vagus nerve with central apoA-IV in the regulation of food intake (Figure 3).
Although platelet apoA-IV receptor has been identified, it is tempting to speculate that apoA-IV
has multiple receptors considering its involvement in a variety of biological processes and effect on
many different tissues. So far, in vitro studies have implied that apoA-IV directly binds to the cell
surface of endothelial cells [118], adipocytes [10], and hepatocytes [9]. As such, it seems reasonable
to propose the isolation of apoA-IV receptor(s) using different cell types and tissues. Furthermore,
apoA-IV exists in lipid-bound state and lipid-free form; the latter takes up more than 50% of the
total circulating apoA-IV [41,42] and seems to display functional difference from the former [5]. This
may add another layer of complexity to the apoA-IV–receptor interaction. Given that apoA-IV has
structural and several functional similarities as apoA-I [35,120,121], it is entirely possible that apoA-IV
and apoA-I bind to common receptor sites. This hypothesis is supported by the findings that both free
apoA-IV and apoA-I can displace HDL on the surface of adult bovine aortic endothelial cells [117]. In
addition, apoA-IV binds to apoA-I/apoA-II receptor sites on mouse adipose cells. However, these data
have been collected using cell cultures in vitro. Whether apoA-IV and apoA-I share similar receptor/s
in vivo awaits further investigation. After all, it is clear that identifying the apoA-IV receptor/s and
related cellular pathways will become our next major advance for the understanding of the molecular
function and therapeutic applications of apoA-IV.
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Figure 1. The metabolism of apoA-IV-containing lipoproteins and possible anti-atherogenic mechanisms
related to apoA-IV. Upon fat absorption, apoA-IV is synthesized, secreted together with chylomicrons
(CM) and transported via lymphatic system to bloodstream. In the circulation, apoA-IV promotes
the activity of lipoprotein lipase (LPL) in the presence of apoC-II. Most apoA-IV dissociates from
chylomicron remnants (CR) and 25% of them are transferred to high-density lipoproteins (HDL), while
the rest are circulating in lipid-free state. (1) ApoA-IV is involved in reverse cholesterol transport, likely
by activating LCAT activity and facilitating cholesterol transport from foam cells or other peripheral
cells to HDL. (2) ApoA-IV can reduce the production of oxidized low-density lipoprotein (Ox-LDL),
which is constantly taken up by macrophages to form foam cells. (3) ApoA-IV acts as anti-inflammatory
agent likely by suppressing P-selectin-mediated leukocyte and platelet adhesion to endothelial cells. It
also interacts with αIIbβ3 integrin and inhibits platelet aggregation.
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Figure 2. ApoA-IV improves glucose homeostasis. (A) ApoA-IV acts downstream of Ca2+-dependent
insulin secretion likely via cAMP pathway. (B) ApoA-IV activates PI3K-mediated Akt phosphorylation
and eventually promotes Glut4 translocation to the plasma membrane for glucose uptake in adipocytes.
(C) ApoA-IV interacts with NR1D1 or NR4A1 in the nucleus to downregulate the expressions of PEPCK
and G6Pase, which are involved in hepatic gluconeogenesis.
Cells 2018, 7, x  12  of  19 
 
 
Figure 2. ApoA‐IV improves glucose homeostasis. (A) ApoA‐IV acts downstream of Ca2+‐dependent 
insulin  secretion  likely  via  cAMP  pathway.  (B)  ApoA‐IV  activates  PI3K‐mediated  Akt 
phosphorylation and eventually promotes Glut4 translocation to the plasma membrane for glucose 
uptake in adipocytes. (C) ApoA‐IV interacts with NR1D1 or NR4A1 in the nucleus to downregulate 
the expressions of PEPCK and G6Pase, which are involved in hepatic gluconeogenesis. 
 
Figure 3. The regulation of food intake by apoA‐IV. ApoA‐IV expressed in the central nervous system 
suppresses  food  intake via PI3K/Akt pathway  in  the hypothalamic neurons. The signal elicited by 
peripheral apoA‐IV is relayed to the brain by vagal nerve to inhibit food intake. 
Depolarization 
Glucose 
Glucose 
ATP/ADP K+ATP channel 
Ca2+ Ca2+ Insulin 
cAMP 
ApoA-IV 
? 
ApoA-IV 
Insulin secretion 
Pancreas β cell 
(A) 
ApoA-IV 
Adipo  
 
 
P P
IRS 
PIP2 
PIP3 
PDK 
Akt P 
Insulin 
receptor 
Glut4 
vesicle 
? ApoA-IV ? 
Glut4 
adipocyte 
(B) 
Gluconeogenesis 
ApoA-IV 
Liver 
 
 
PEPCK 
G6Pase 
NR1D1/NR4A1 
Nucleus hepatocyte 
(C) 
Glucose 
uptake 
 
 
P P
IRS 
PIP2 
PIP3 
PDK 
Insulin 
receptor ? 
Central 
ApoA-IV 
? 
Akt P 
Food intake 
Hypothalamic neuron 
Hypothalamus 
Food intake 
Peripheral apoA-IV 
efferent 
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peripheral apoA-IV is relayed to the brain by vagal nerve to inhibit food intake.
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